Abstract
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT
Current Radiopharmaceuticals
Title: Targeted Alpha Therapy with 213Bi
Volume: 4 Issue: 4
Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis
Affiliation:
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT
Abstract: The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.
Export Options
About this article
Cite this article as:
Morgenstern Alfred, Bruchertseifer Frank and Apostolidis Christos, Targeted Alpha Therapy with 213Bi, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040295
DOI https://dx.doi.org/10.2174/1874471011104040295 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Hydrophobic Modification of Copper Nanospheres for Incorporation into Poloxamer Micelles, Aggregated Micellar Nanocages and Supramolecular Assemblies
Current Nanomedicine Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry Cellular Efflux of cAMP and cGMP - A Question about Selectivity
Mini-Reviews in Medicinal Chemistry Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention
Letters in Drug Design & Discovery KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
Current Medicinal Chemistry - Anti-Cancer Agents A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Brain Perfusion In Sepsis
Current Vascular Pharmacology Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design